FIRST PATIENT SUCCESSFULLY DOSED
The first patient has enrolled in the Phase I clinical trial and was dosed on Sunday, April 14. No acute safety issues were reported.
The first patient has enrolled in the Phase I clinical trial and was dosed on Sunday, April 14. No acute safety issues were reported.